Erudio Healtherudio.com
Indication
HER2-positive breast cancer trials: what clinicians said in public
No HCP commentary report on a trial in HER2-positive breast cancer yet. Erudio has found public clinician commentary on 2 clinical trials in HER2-positive breast cancer: DESTINY-Breast05 and DESTINY-Breast09. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| DESTINY-Breast05 NCT04622319 · Daiichi Sankyo DeepView → | HER2-positive residual invasive breast cancer following neoadjuvant therapy | Phase 3 | Deep | View | |||
| DESTINY-Breast09 NCT04784715 · AstraZeneca DeepView → | first-line HER2-positive metastatic breast cancer | Phase 3 | Deep | View | |||